CN114129605A - Application of blueberry anthocyanin - Google Patents

Application of blueberry anthocyanin Download PDF

Info

Publication number
CN114129605A
CN114129605A CN202111560214.0A CN202111560214A CN114129605A CN 114129605 A CN114129605 A CN 114129605A CN 202111560214 A CN202111560214 A CN 202111560214A CN 114129605 A CN114129605 A CN 114129605A
Authority
CN
China
Prior art keywords
blueberry anthocyanin
application
cancer cell
blueberry
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111560214.0A
Other languages
Chinese (zh)
Inventor
宋冬妍
温继龙
王宁
李殿俊
于航
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Liansheng Biotechnology Co ltd
Original Assignee
Heilongjiang Liansheng Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang Liansheng Biotechnology Co ltd filed Critical Heilongjiang Liansheng Biotechnology Co ltd
Priority to CN202111560214.0A priority Critical patent/CN114129605A/en
Publication of CN114129605A publication Critical patent/CN114129605A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An application of blueberry anthocyanin relates to an application of blueberry anthocyanin. The invention provides application of blueberry anthocyanin. An application of blueberry anthocyanin, namely an application of a blueberry anthocyanin extract in preparation of anti-hepatoma cell line medicines. The advantages are that: since the expression of GADD45A, GADD45B, DDIT4, CDKN1A, CHAC1ATF-4 and EPHA2 is more highly transcribed in HepG-2 cells after blueberry anthocyanin treatment, blueberry anthocyanin can induce apoptosis through related pathways; therefore, the blueberry anthocyanin can be used as an auxiliary component for preventing cancers and used for preparing anti-hepatoma cell line medicines.

Description

Application of blueberry anthocyanin
The application is a divisional application of an application with the application date of 2021, 8 and 27, the application number of 202110996223.8 and the name of application of blueberry anthocyanin.
Technical Field
The invention relates to application of blueberry anthocyanin.
Background
Blueberries are members of the ericaceae and bilberry genera and are known for their high content of flavonoids (anthocyanins, flavonols, procyanidins) and other phenolic compounds. The flavonoid is a three-membered ring compound and has the effect of protecting the heart, known that low-density lipoprotein is harmful to human bodies and is easy to cause coronary heart disease, and the flavonoid can inhibit the generation of the harmful low-density lipoprotein and has the effect of reducing thrombosis. The investigation proves that the mortality rate of coronary heart disease is lower for patients with high flavonoid intake. Anthocyanins belong to the flavonoid class of phenolic compounds, and are potent antioxidants that protect the human body from a harmful substance called free radicals. Anthocyanins can also enhance vascular elasticity, improve circulatory system and smoothness of skin, inhibit inflammation and allergy, and improve joint flexibility.
Disclosure of Invention
The invention provides application of blueberry anthocyanin.
An application of blueberry anthocyanin, an application of a blueberry anthocyanin extract in preparing an anti-tumor medicament; the mass fraction of the blueberry anthocyanin in the blueberry anthocyanin extract reaches more than 95%.
The invention has the advantages and the principle that:
the cause of apoptosis is as follows:
active oxygen is an apoptosis inducer for cells. Some of the agents that trigger apoptotic patterns are stimulators of cellular oxidative metabolism. Bufalin (Bufalin) has been reported to induce autophagy of cancer cells by producing reactive oxygen species in human colon cancer cells. Therefore, reactive oxygen species are considered to be essential mediators for monitoring cancer cell apoptosis. Cytochrome c is a key factor in the apoptotic process in this mechanism. When some factors induce disruption of the outer mitochondrial membrane, some mitochondrial apoptotic factors, such as cytochrome c, are released into the cytoplasm. Cytochrome c present in the cytoplasm may induce activation of caspase, resulting in apoptosis. It has been shown that cytoplasmic cytochrome c is involved in caspase-9 dependent activation of caspase-3, initiating the apoptotic program. Furthermore, it has been reported that a decrease in matrix metalloproteinases can trigger the opening of the mitochondrial pore, which in turn may release cytochrome c from the mitochondria into the cytoplasm.
② the Bax/Bcl-2 ratio is considered as the mitochondrion mediated apoptosis marker, the apoptosis of the cell is related to whether the Bax and Bcl-2 proteins are expressed in balance. Bax can increase permeability of the mitochondrial membrane, leading to entry of proteins in the inter-mitochondrial membrane space (cytochrome c) into the cytoplasm. Cytochrome c can initiate caspase activation and apoptosis. Bcl-2 belongs to an anti-apoptotic protein and can inhibit Bax-mediated mitochondrial membrane permeability.
③ the MAPK pathway is important for p38, JNK, NFKB and p53 to regulate cell proliferation and apoptosis. It is well known that the p53 protein plays an important role in growth arrest and apoptosis after cellular stress, including deoxyribonucleic acid damage, oxidative stress, and activation of oncogenes. The p53 protein is used as the transcription activator of p53 regulating gene and can induce cell cycle arrest, cell senescence or apoptosis.
DNA damage-inducing transcript 4(DDIT4) and growth arrest and DNA damage inducers alpha and beta (GADD 45A and GADD45B, respectively) are involved in the regulation of cell growth and apoptosis. GADD45A and GADD45B play important roles in negative growth control, including cell death and inhibition of cell growth. The proteins encoded by GADD45A and GADD45B were reported to be regulated by p53 tumor suppressor. The two proteins can also activate the p38/JNK kinase pathway and apoptosis through stress-responsive MTK1/MEKK4 kinase.
It is known that CHAC1 and ATF-4 are involved in intrinsic apoptotic signaling pathways in response to Endoplasmic Reticulum (ER) stress. ER stress-dependent apoptosis is mediated by activation of human caspases and pro-apoptotic members of the Bcl-2 family. Cyclin-dependent kinase inhibitor 1(CDKN1A) is involved in the positive regulation of reactive oxygen metabolic processes. CDKN1A (p21) can induce mitochondrial dysfunction and reactive oxygen species production through the series of signaling by GADD45-MAPK 14(p38 MAPK) -grb 2-TGFBR 2-TGFbeta. EPHA2 is an essential p 53-independent, caspase-8-dependent pro-apoptotic factor. The expressions of GADD45A, GADD45B, DDIT4, CDKN1A, CHAC1ATF-4 and EPHA2 are more highly transcribed in HepG-2 cells after being treated by blueberry anthocyanin, so that the blueberry anthocyanin can induce apoptosis through related pathways; therefore, the blueberry anthocyanin can be used as an auxiliary component for preventing cancers and is used for preparing anti-tumor drugs, particularly for tongue squamous cancer cell lines, non-small cell lung cancer cell lines, liver cancer cell lines and prostate cancer cell lines.
Detailed Description
The first embodiment is as follows: the embodiment is an application of blueberry anthocyanin, and the application of a blueberry anthocyanin extract in preparing an anti-tumor medicament; the mass fraction of the blueberry anthocyanin in the blueberry anthocyanin extract reaches more than 95%.
The second embodiment is as follows: the present embodiment differs from the present embodiment in that: the blueberry anthocyanin extract is used for preparing a medicine for resisting a head and neck squamous cell carcinoma cell line. The rest is the same as the first embodiment.
The third concrete implementation mode: the second embodiment differs from the first embodiment in that: the head and neck squamous carcinoma cell line is tongue squamous carcinoma cell SCC 15. The rest is the same as the second embodiment.
The fourth concrete implementation mode: the present embodiment differs from the present embodiment in that: the blueberry anthocyanin extract is used for preparing anti-hepatoma cell line medicines. The rest is the same as the first embodiment.
The fifth concrete implementation mode: the fourth difference between the present embodiment and the specific embodiment is: the liver cancer cell line is liver cancer cell HuH-7 or liver cancer cell HLF. The rest is the same as the fourth embodiment.
The sixth specific implementation mode: the present embodiment differs from the present embodiment in that: the blueberry anthocyanin extract is used for preparing a medicine for resisting a prostate cancer cell line. The rest is the same as the first embodiment.
The seventh embodiment: the sixth difference from the present embodiment is: the prostate cancer cell line is prostate cancer cell C4-2B. The rest is the same as the sixth embodiment.
The specific implementation mode is eight: the present embodiment differs from the present embodiment in that: the blueberry anthocyanin extract is used for preparing a non-small cell cancer cell line resistant medicament. The rest is the same as the first embodiment.
The specific implementation method nine: eighth embodiment differs from the eighth embodiment in that: the non-small cell cancer cell line is a non-small cell lung cancer cell H460. The rest is the same as the embodiment eight.
The invention is not limited to the above embodiments, and one or a combination of several embodiments may also achieve the object of the invention.
The following experiments are adopted to verify the effect of the invention:
example 1: an application of blueberry anthocyanin, an application of a blueberry anthocyanin extract in preparing an anti-tumor medicament; the mass fraction of the blueberry anthocyanin in the blueberry anthocyanin extract is 99.3%; in particular to application of the blueberry anthocyanin extract in preparing medicines for resisting squamous cell carcinoma SCC15, liver cancer cell HuH-7, liver cancer cell HLF, prostate cancer cell C4-2B and non-small cell lung cancer cell H460.
And (3) cell viability detection:
reagent: cell counting Kit CCK8 Kit (same as Japan), DMEM high-sugar liquid Medium, RPMI Medium 1640basic, normal saline, pancreatin Cell digestive juice, special fetal calf serum, penicillin-streptomycin solution.
Consumable material: pasteur pipet, 25cm square culture bottle with inclined mouth, 15mL aseptic centrifuge tube, 96-hole cell culture plate.
Medicine preparation: the purity of the blueberry anthocyanin extract is 99.3 percent.
The experimental method comprises the following steps:
(1) cancer cell and media selection: selecting experimental cancer cells and a liquid culture medium as shown in table 1; secondly, adding bovine serum and a penicillin/streptomycin solution into the liquid culture medium to prepare a complete culture medium, wherein the volume ratio of the liquid culture medium to the bovine serum is 9: 1; the volume ratio of the liquid culture medium to the penicillin/streptomycin solution is 99:1, the concentration of penicillin G sodium salt in the penicillin/streptomycin solution is 10KU/mL, and the concentration of streptomycin sulfate is 10 mg/mL.
TABLE 1
Figure BDA0003420292530000031
Figure BDA0003420292530000041
(2) The cell culture method comprises the following steps: taking out the frozen tube from a refrigerator at minus 80 ℃, quickly placing the frozen tube in a water bath kettle at 37 ℃, incubating for 1-2 min, taking out, sucking out the experimental cancer cells (shown in table 1) into a 15mL centrifuge tube, adding 10mL of complete culture medium, uniformly mixing, centrifuging (1500rpm for 5min), discarding the supernatant after centrifugation, suspending the cells by using 4mL of complete culture medium, transferring the cells to an oblique-mouth cell culture bottle, placing the cells in a 37 ℃ C., and 5% CO2Carrying out static culture in an incubator;
(3) cell proliferation and toxicity detection: firstly, discarding a culture medium in a bottle, adding 1mL of physiological saline to clean cells (when the physiological saline is added, placing a pipettor at the bottom of the bottle, not directly cleaning the pipettor by using a gun, slightly shaking the culture bottle), sucking out the physiological saline, adding 1mL of trypsin digestive juice, digesting the cells to a cell suspension (or semi-suspension) state, adding 4mL of complete culture medium, resuspending cells by using a Pasteur tube, centrifuging (1500rpm, 5min), discarding supernatant, and adding 4mL of complete culture medium to suspend the cells to obtain cell suspension;
(4) preparing 100 mu L of cell suspension in a 96-well plate; the plates were pre-incubated in an incubator for 24 hours (37 ℃ C., 5% CO)2)。
(5) Dissolving the blueberry anthocyanin extract with complete culture medium according to the blueberry anthocyanin concentrations of 2mg/mL, 4mg/mL, 8mg/mL, 12mg/mL, 16mg/mL, 20mg/mL and 24mg/mL respectively to prepare a blueberry anthocyanin-containing culture medium, and filtering with a 0.22-micrometer filter membrane;
(6) grouping according to an additive group, an additive group (0) (namely, no additive group) and a blank group, wherein the additive group comprises the following components in parts by weight: adding 100 mu L of blueberry anthocyanin-containing culture medium with different blueberry anthocyanin concentrations into each hole of the culture plate of the dosing group, and adding the culture plate of the dosing group; 0, dosing group: adding 100 mu L of culture medium into each hole of the culture plate of the drug adding group 0 to obtain the drug adding group 0 culture plate; blank group: each hole in the blank group of culture plates is a hollow hole, so that a blank group of culture plates is obtained;
(7) and (4) incubating the medicated group culture plate, the 0 medicated group culture plate and the blank group culture plate obtained in the step (6) in an incubator for 24 h.
(8) The Cell counting Kit CCK8 Kit was diluted with liquid medium at a ratio of 1:10 to obtain a diluted CCK-8 solution.
(9) Adding 100 mu L of diluted CCK-8 solution into each hole of the culture plate added with the medicine in the step (7) to obtain a culture plate added with the medicine CCK-8; in the step (7), 100 mu L of diluted CCK-8 solution is added into each hole of the 0-medicine-adding group culture plate to obtain a 0-medicine-adding group CCK-8 culture plate; adding 100 mu L of liquid culture medium into each hole of the hollow white tissue culture plate in the step (7) to obtain a blank control culture plate; (Care not to generate bubbles in the well, which would affect the OD reading).
(10) And incubating the drug-adding group CCK-8 culture plate, the 0 drug-adding group CCK-8 culture plate and the blank control culture plate in an incubator for 4 hours.
(11) And measuring the absorbance of each hole of the drug adding group CCK-8 culture plate, the 0 drug adding group CCK-8 culture plate and the blank control culture plate at 450nm by using an enzyme-labeling instrument.
The Kit is used for detecting the Cell proliferation-toxicity of a head and neck squamous Cell carcinoma Cell line by using a Cell Counting Kit-8, wherein the Cell Counting Kit-8 is called CCK-8 for short, and is a rapid high-sensitivity detection Kit which is based on WST-8 (chemical name: 2- (2-methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2, 4-disulfobenzene) -2H-tetrazole monosodium salt) and is widely applied to Cell proliferation and cytotoxicity. The working principle is as follows: in the presence of an electron coupling agent, it is reduced by mitochondrial dehydrogenases to produce a highly water-soluble orange-yellow formazan product (formazan). The shade of color is proportional to the proliferation of cells and inversely proportional to cytotoxicity. OD value was measured at a wavelength of 450nm using a microplate reader, indirectly reflecting the number of living cells.
The activity was calculated, and the calculation results are shown in table 2:
cell viability (%) ([ a (dosed) -a (blank) ]/[ a (0 dosed) -a (blank) ] × 100
A (dosing): absorbance of the drug adding group hole; a (blank): absorbance of blank set wells; a (0 dosing): 0 absorbance of the wells of the kit.
TABLE 2
Figure BDA0003420292530000051
Figure BDA0003420292530000061
As can be seen from Table 2, the survival rates of the tonsil cancer cell lines, the non-small cell lung cancer cell lines and the liver cancer cell lines are gradually reduced along with the increase of the concentration of the blueberry anthocyanin, and the inhibition effect on the cell growth is gradually obvious, so that the growth of the tonsil cancer cell lines, the non-small cell lung cancer cell lines and the liver cancer cell lines is obviously influenced by the blueberry anthocyanin, and the inhibition effect and the concentration of the blueberry anthocyanin form a dose-dependent relationship. In contrast, prostate cancer cell lines are more sensitive to blueberry anthocyanin extract, and prostate cancer cells show high inhibition rate in low dose of blueberry anthocyanin pure extract and do not change with the change of anthocyanin dose.
And (4) conclusion: according to the apoptosis mechanism of HepG-2 cells, the blueberry anthocyanin extract has obvious cancer cell apoptosis inducing effect on tongue squamous cancer cell lines, non-small cell lung cancer cell lines, liver cancer cell lines and prostate cancer cell lines.

Claims (2)

1. The application of the blueberry anthocyanin is characterized in that: the application of the blueberry anthocyanin extract in preparing anti-hepatoma cell line medicines; the mass fraction of the blueberry anthocyanin in the blueberry anthocyanin extract reaches more than 95%.
2. The application of the blueberry anthocyanin according to claim 1, wherein the liver cancer cell line is liver cancer cell HuH-7 or liver cancer cell HLF.
CN202111560214.0A 2021-08-27 2021-08-27 Application of blueberry anthocyanin Withdrawn CN114129605A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111560214.0A CN114129605A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110996223.8A CN113599410A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202111560214.0A CN114129605A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110996223.8A Division CN113599410A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin

Publications (1)

Publication Number Publication Date
CN114129605A true CN114129605A (en) 2022-03-04

Family

ID=78309589

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111560214.0A Withdrawn CN114129605A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202111559868.1A Pending CN114191462A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202110996223.8A Pending CN113599410A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202111560195.1A Pending CN114177214A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202111559868.1A Pending CN114191462A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202110996223.8A Pending CN113599410A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin
CN202111560195.1A Pending CN114177214A (en) 2021-08-27 2021-08-27 Application of blueberry anthocyanin

Country Status (1)

Country Link
CN (4) CN114129605A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145780A (en) * 2012-12-20 2013-06-12 天津科技大学 Preparation method of blueberry anthocyanin and application of blueberry anthocyanin prepared

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
CN101864351B (en) * 2010-06-25 2012-05-09 裴光泰 Fructose-free blueberry wine and preparation method thereof
CN106810904B (en) * 2017-01-11 2020-04-17 心颐和国际中医药投资控股（北京）有限公司 Method for extracting anthocyanin components

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145780A (en) * 2012-12-20 2013-06-12 天津科技大学 Preparation method of blueberry anthocyanin and application of blueberry anthocyanin prepared

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
YUEHUA WANG: "Blueberry Malvidin-3-galactoside Suppresses Hepatocellular Carcinoma by Regulating Apoptosis, Proliferation, and Metastasis Pathways In Vivo and In Vitro", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 *
孙倩怡等: "蓝莓花青素的研究进展", 《食品工业科技》 *
艾福录等: "蓝莓花青素对人胃腺癌BGC-823细胞增殖、侵袭的影响及机制研究", 《世界中医药》 *
詹玮等: "蓝莓花青素对HepG2细胞凋亡及组蛋白乙酰化修饰的影响", 《中国普通外科杂志》 *
陈晶晶: "蓝莓花青素苷元的制备技术及其对HepG2细胞增殖抑制作用研究", 《中国优秀硕士学位论文全文数据库》 *

Also Published As

Publication number Publication date
CN113599410A (en) 2021-11-05
CN114177214A (en) 2022-03-15
CN114191462A (en) 2022-03-18

Similar Documents

Publication Publication Date Title
Cao et al. Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways
Yuan et al. Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo
Zhang et al. Celastrus orbiculatus extract induces mitochondrial-mediated apoptosis in human hepatocellular carcinoma cells
Gao et al. Daucosterol induces autophagic-dependent apoptosis in prostate cancer via JNK activation
JP4594734B2 (en) Use of endoperoxides for the treatment of infections caused by flaviviridae viruses including hepatitis C, bovine viral diarrhea and swine fever virus
WO2021259772A1 (en) Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by coronaviridae
KR20190003421A (en) Composition for preventing, improving or treating of fibrosis
JP2012511522A (en) Composition for prevention and treatment of viral infection
Li et al. Antibacterial and antitumor activity of secondary metabolites of endophytic fungi ty5 from Dendrobium officinale
CN101805246B (en) Urushiol compound and medicinal composition thereof, preparation method and application thereof
CN114129605A (en) Application of blueberry anthocyanin
KR20150014033A (en) Food composition for liver activity contaning Water extract of Cordyceps militaris and its manufacturing method
Mohammadi Motlagh et al. Anti-angiogenic effect of aqueous extract of shallot (Allium ascalonicum) bulbs in rat aorta ring model
CN111658655A (en) Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug
US6440451B1 (en) Use of crataegus formulations for prophylaxis and treatment of neoplastic diseases
CN105920019A (en) Pharmaceutical composition containing ursolic acid and sorafenib and application thereof in preparing antineoplastic medicaments
CN109908127B (en) Application of compounds in preparation of anti-small RNA virus drugs
CN102178697B (en) Compound leech capsule and preparation method thereof
Li et al. Curcumin exerts protective effect on PC12 cells against lidocaine-induced cytotoxicity by suppressing the formation of NLRP3 inflammasome.
KR100671762B1 (en) Composition of herb medicine for preventing and curing cancer
CN108096239B (en) A pharmaceutical composition for treating brain glioma and hepatocarcinoma
Wang Effects of fresh royal jelly on the proliferation of human hepatoma cell line SMMC-7721
Banjerdpongchai et al. Phytochemicals from Goniothalamus griffithii induce human cancer cell apoptosis
CN110478346A (en) Antineoplastic pharmaceutical compositions and its application
JP2010502655A (en) Application of Solidago radish in the preparation of drugs for antiviral treatment and prevention

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220304